Registre simple
dc.contributor |
Universitat de Vic. Càtedra de la Sida i Malalties Relacionades |
|
dc.contributor.author |
Surdo, M.
|
|
dc.contributor.author |
Alteri, C.
|
|
dc.contributor.author |
Puertas, M.C.
|
|
dc.contributor.author |
Saccomandi, P.
|
|
dc.contributor.author |
Parrotta, L.
|
|
dc.contributor.author |
Swenson, L.
|
|
dc.contributor.author |
Chapman, D.
|
|
dc.contributor.author |
Costa, G.
|
|
dc.contributor.author |
Artese, A.
|
|
dc.contributor.author |
Balestra, E.
|
|
dc.contributor.author |
Aquaro, S.
|
|
dc.contributor.author |
Alcaro, S.
|
|
dc.contributor.author |
Lewis, M.
|
|
dc.contributor.author |
Clotet, Bonaventura
|
|
dc.contributor.author |
Harrigan, R.
|
|
dc.contributor.author |
Valdez, H.
|
|
dc.contributor.author |
Svicher, V.
|
|
dc.contributor.author |
Perno, C.F.
|
|
dc.contributor.author |
Martinez Picado, Francisco Javier
|
|
dc.contributor.author |
Ceccherini-Silberstein, Francesca
|
|
dc.date.accessioned |
2015-04-20T11:02:30Z |
|
dc.date.available |
2015-04-20T11:02:30Z |
|
dc.date.created |
2015 |
|
dc.date.issued |
2015 |
|
dc.identifier.citation |
Surdo, M., Alteri, C., Puertas, M. C., Saccomandi, P., Parrotta, L., Swenson, L., et al. (2015). Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029. Clinical Microbiology and Infection, 21(1), 103.e1-103.e6. |
ca_ES |
dc.identifier.issn |
1198-743X |
|
dc.identifier.uri |
http://hdl.handle.net/10854/3997 |
|
dc.description.abstract |
We characterized maraviroc susceptibility of dual/mixed tropic
viruses from subjects enrolled onto phase IIb study A4001029.
Maraviroc baseline plasma samples from 13 multidrugexperienced
subjects were sequenced and the HIV-1-env gene
cloned into pNL4.3Δenv to obtain recombinant viruses. The V3
region was sequenced by the Sanger method and ultradeep
sequencing. By analysing subjects having a weighted optimized
background therapy susceptibility (wOBT) score of <1, 3/7
subjects were characterized by good in vivo and in vitro response
to maraviroc therapy. Molecular docking simulations allowed us
to rationalize the maraviroc susceptibility of dual/mixed tropic
viruses. A subset of subjects with dual/mixed tropic viruses
responded to maraviroc. Further investigations are warranted of
CCR5 antagonists in subjects carrying dual/mixed tropic virus
that explore the feasible use of maraviroc in subjects that is
potentially larger than those infected with a pure R5 virus. |
ca_ES |
dc.format |
application/pdf |
|
dc.format.extent |
6 p. |
ca_ES |
dc.language.iso |
eng |
ca_ES |
dc.publisher |
Wiley |
ca_ES |
dc.rights |
Tots els drets reservats |
ca_ES |
dc.rights |
(c) Wiley |
|
dc.subject.other |
Sida -- Tractament |
ca_ES |
dc.title |
Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029 |
ca_ES |
dc.type |
info:eu-repo/semantics/article |
ca_ES |
dc.identifier.doi |
https://doi.org/10.1016/j.cmi.2014.08.002 |
|
dc.rights.accessRights |
info:eu-repo/semantics/closedAccess |
ca_ES |
dc.type.version |
info:eu-repo/publishedVersion |
ca_ES |
dc.indexacio |
Indexat a SCOPUS |
ca_ES |
Text complet d'aquest document
Registre simple